2023
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.Peer-Reviewed Original ResearchConceptsHER2 mRNA levelsIHC 0MRNA levelsOncotype DX recurrence score resultsEstrogen receptor-positive breast cancerReceptor-positive breast cancerCurrent adjuvant chemotherapyOncotype DX assayRecurrence Score resultsPositive breast cancerInvasive breast carcinomaIHC score 0Adjuvant chemotherapyQuantitative RT-PCRBreast carcinomaPositive statusScore 0Breast cancerStage IYale cohortHigher mRNA levelsCancerRT-PCRPatientsHER2
2016
Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years
McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A. Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years. Journal Of Oncology 2016, 2016: 4324863. PMID: 27382369, PMCID: PMC4921638, DOI: 10.1155/2016/4324863.Peer-Reviewed Original ResearchPathological complete response rateTriple-negative breast cancerComplete response rateNeoadjuvant chemotherapyRates of pCRTime period 2PCR rateResponse rateAnthracycline/taxaneDual HER2 blockadeIntroduction of carboplatinType of chemotherapyBreast cancer patientsNegative breast cancerTime period 1HER2 blockadeNeoadjuvant regimensAdjuvant regimensClinical characteristicsHER2 positivityOpportunity trialCancer patientsBreast carcinomaBreast cancerStage I